cyrilzakka/clinical-trials huggingface dataset:
Transcranial Alternating Current Stimulation (tACS) to Improve Motor Skill Acquisition in Stroke Patients

Hand motor function is often severely affected in stroke patients and its recovery is one primary goal in stroke rehabilitative treatment programs. Recently, theta-gamma transcranial alternating current stimulation (tACS) has been shown to enhance motor skill acquisition in healthy individuals. The aim of the present study is to examine the effect of theta-gamma tACS on motor skill acquisition in chronic stroke patients.

Hand motor function is often severely affected in stroke patients and recovery of function is a primary goal in stroke rehabilitative treatment programs. Recently, theta-gamma tACS has been shown to enhance motor skill acquisition in healthy individuals \[Akkad et al.2021\]. The aim of the present study is to examine the effect of theta-gamma tACS on motor skill acquisition in chronic stroke patients.

In a randomized, controlled, triple-blind trial, chronic stroke patients with an initially impaired hand motor function will receive either (i) theta-gamma peak stimulation (TGP) or (ii) sham stimulation. TGP stimulation significantly improved motor learning in the study by Akkad et al (2021) compared to sham stimulation. tACS will be delivered through a five-electrode montage centered over the sensorimotor cortex on the lesioned side of the brain for approximately 38 min. During stimulation patients will perform a motor skill acquisition task performed with the affected hand. The task consists of short repetitive trials in which participants alternately press two buttons with their thumb. It is designed in a way that participants can improve their performance, more precisely the speed of button presses, and are encouraged to do so. To reduce skin sensations beneath the stimulation electrodes and thereby improve blinding compared to sham stimulation, a local anesthetic consisting of lidocaine and prilocaine will be administered underneath the stimulation electrodes.

Based on the results of the study by Akkad et al. (2021) and on the assumption that theta-gamma phase amplitude coupling is a key mechanism for motor skill acquisition, the investigators hypothesize that motor skill acquisition will differ significantly between the TGP and sham group.

Eligibility Criteria:
Inclusion Criteria:

* German-speaking
* ability to perform a thumb movement task with the affected hand
* first-ever clinical ischemic stroke in the chronic phase
* persistent mild motor deficit of the upper extremity or motor deficit of the upper extremity in the acute phase over \>24h

Exclusion Criteria:

* pronounced cognitive deficits
* history of major neurological or psychiatric illness other than stroke
* epilepsy or epileptic seizure in the history
* any devices or implants in the head region (e.g. cochlear implant, aneurysm clips),
* implanted pacemaker or medical pumps
* intake of psychotropic medication
* allergy to any ingredient of the local anesthetic cream
* pregnancy
Same Day Discharge for Wedge Resection

Monitoring carefully selected participants to determine if participants can be safely discharged the same day of pulmonary resection

Determination of the feasibility of implementing a same day discharge program after minor pulmonary surgery. This will be determined by evaluating the percentage of participants who have chest tubes removed successfully, as well as evaluating the percentage of participants who would be classified as discharged on the day of surgery. The investigators will also be evaluating morbidity associated with this protocol by capturing rates of pleural reintervention.

Eligibility Criteria:
Inclusion Criteria:

Patients aged 18 years of age and older who are scheduled to undergo an elective minimally invasive wedge resection of their lung.

Exclusion Criteria:

1. Pulmonary function tests demonstrating forced expiratory volume in 1 second (FEV1) \<50% predicted, FEV1 \<1.5L and/or diffusion lung capacity of carbon monoxide (DLCO) \<50% predicted.
2. Patient receives an intraoperative pleurodesis.
3. Conversion to open thoracotomy or mini thoracotomy intraoperatively.
4. Active pregnancy.
5. Thoracic Revised Cardiac Risk Index Score (ThRCRI)8 \>2.
6. Underlying cognitive disorder resulting in inability to complete activities of daily living.
Safety and Efficacy of the Tao Facemask for Positive Pressure Ventilation in the Patients With Significantly Elevated BMIs

The Tao Mask is a new novel facemask for positive pressure ventilation which has recently been demonstrated (MUSC study Pro00047645) to have superior performance to our conventional (standard) positive pressure mask in a random distribution of patients with experiences users. This additional study will extend our investigation of the new masks capabilities by studying it's performance in the morbidly obese - which are more challenging patients to ventilate by mask. Our hypothesis is that the Tao mask will be even more effective in this challenging population than in the random distribution of patients.


Eligibility Criteria:
Inclusion Criteria:

1. Age \>18 years.
2. BMI of \>40.
3. Patients having elective surgery (designated by priority level of 5) requiring general endotracheal anesthesia.

Exclusion Criteria:

1. Need for awake intubation based on standard preoperative evaluation by the attending anesthesiologist.
2. Increased risk for aspiration of gastric contents due to full stomach, pregnancy, gastro-esophageal reflux disease, and/or hiatal hernia as identified during the pre-operative assessment.
3. Previous tracheostomy procedure.
4. Patient is cognitively incapable of providing their consent for the study.
Clinical Study of the Solo+ Tympanostomy Tube Device

The objective of this study is to evaluate the safety and performance of the Solo+ Tympanostomy Tube Device for the placement of tympanostomy tubes (grommets) in paediatric patients undergoing a tympanostomy procedure

The study will be a multi-site, prospective, treatment-only study of the Solo+ Tympanostomy Tube Device. Patients will already have a scheduled tympanostomy procedure.

Eligibility Criteria:
Inclusion Criteria:

* Listed for bilateral tympanostomy tube insertion

Exclusion Criteria:

* Anatomy that precludes sufficient visualisation of both the left and right eardrum
* Narrow ear canals
* Anatomy that precludes safe access to both the left and right eardrum
* Membrane \>25% sclerosis
* Congenital or craniofacial abnormalities
* No available baseline audiometry and tympanometry
The Analysis of the Impact of 5-minute Massage Session on the Muscle Stiffness and Tone

The study design was a randomised, controlled, parallel, two-arm trial. The subjects were randomly assigned to one of the study groups: the intervention group or the control group. The passive mechanical properties, i.e. the stiffness and tone of the medial and lateral gastrocnemius muscle (dominant leg) were assessed. Measures were taken twice: in the intervention group before and after the 5-minute massage session, and in the control group at the beginning of the meeting and again after 5 minutes.

The purpose of this study was to determine whether a 5-minute massage, applied to healthy individuals, may change the passive mechanical muscle properties, which supposedly may prevent MSDs. The study is carried out on the medial and lateral gastrocnemius muscles because of their accessibility and crucial role in locomotion. MyotonPRO and TMG S2 devices were used to assess the stiffness and radial muscle displacement of the gastrocnemius muscle respectively.

Eligibility Criteria:
Inclusion Criteria:

* age between 19 and 24 years;
* healthy individuals, with no lower limb pathology;
* PA≥600 MET-min/week assessed by IPAQ questionnaire;
* no medical contraindication of massage therapy;
* body mass index 18,5 \< BMI ≤ 25kg/m2
* signing the informed consent.

Exclusion Criteria:

* pregnant women;
* individuals suffering from neurologic or orthopaedic problems;
* lower limb surgical interventions;
* cancers;
* musculoskeletal disorders
* body mass index 18,5 \> BMI ≥ 25kg/m2
* the lack of informed consent.
Comparison of hhCG With hCG+ß in the Early Prediction of Ongoing Pregnancy.

Proof of concept study for the prediction of ongoing pregnancy in women undergoing In-Vitro Fertilization (IVF), using hyperglycosylated human chorionic gonadotropin (hhCG), early after In-Vitro Fertilization and fresh Embryo Transfer (IVF-ET).


Eligibility Criteria:
Inclusion criteria:

* Written informed consent
* Patients undergoing their first or second IVF-ET cycle
* Age 18-45 years
* Use of Ovitrelle for final follicular maturation and luteinization
* Fresh or Frozen day-5 blastocysts transrer (Autologus or Egg donation)

Exclusion criteria:

* Gestational surrogacy (patient's eggs used for pregnancy in a surrogate mother)
* Canceled IVF cycles
* GnRH agonist triggering cycles in the case of fresh ET.
Botulinum A Toxin in Patients With Parkinson's Disease

The researchers investigated the effectiveness and safety of BoNT/A injected into the detrusor muscle in patients with PD and MSA all of whom had detrusor muscle overactivity unresponsive to conventional medical therapy.

Patients included will have overactive bladder symptoms refractory to medical therapy. Other causes of overactive bladder symptoms including urogenital prolapse and recurrent urinary tract infections were excluded. None of the patients will be under anticoagulant therapy or drugs interfering with neuromuscular transmission. The study was approved by the local ethical committee and patients gave their informed consent. Patients will be informed about the possible need for intermittent catheterization after BoNT/A treatment.

As outcome measures we assessed clinical and urodynamic variables.

Eligibility Criteria:
Inclusion Criteria:

* Patients with overactive bladder symptoms refractory to medical therapy.

Exclusion Criteria:

* Other causes of overactive bladder symptoms including urogenital prolapse and recurrent urinary tract infections were excluded.
* Concomitant anticoagulant therapy or drugs interfering with neuromuscular transmission.
* Neuromuscular disease like Lambert-Eaton syndrome.
Monitoring MRI Changes Before and During Radiotherapy Treatment of Brain Tumors

This study aims to evaluate anatomical and functional changes during RT for patients receiving fractionated RT for brain tumors. Anatomical changes during RT will be registered and analyzed and if needed the radiotherapy plan will be modified for the individual patient. This means that the "to be irradiated volume" will be modified according to the shape changes of the tumor. The functional MRI sequences will be used to evaluate what parameters, and at which time point, are important for radiotherapy outcome.


Eligibility Criteria:
Inclusion Criteria:

* Primary brain tumor (WHO IV, GBM); treated with fractionated radiotherapy with or without preceding surgery. Systemic treatment is allowed before and during radiotherapy.
* Brain metastasis (from a solid extracranial tumor) eligible for treatment with fractionated radiotherapy with or without preceding surgery. Systemic treatment is allowed before and during radiotherapy.

Also, postoperative patients with a macroscopic residual tumor lesion can be included (the diagnosis of residual diseases is defined by the treating neurosurgeon or on the MRI executed within 24 hours after the surgery, the diagnosis of residual macroscopic disease should always be confirmed during the neuro-oncology multidisciplinary meeting).

Exclusion Criteria:

* Patients receiving Whole Brain RT (WBRT)
* Patient with a poor kidney function (GFR \< 30 mL/min; CKD 4 and 5; patients on dialysis and patients with acute kidney insufficiency)
* None, doubtful or very small (\<5 mm in its largest dimension) contrast enhancing lesion
* Patients with a contraindication for MRI
Post-Partum Haemorrhage (PPH) Improvement of Skills With Actor Simulations

Pre test and post test questionnaire for evaluation of skills and teamwork capacities in PPH management

Obstetricians, midwives, anesthesiologists, surgical theatre nurses, and sanitary collaborators are enrolled voluntary in a teamwork (2 gynecologists, 2 midwives, 1 anesthesiologist, 1 surgical theatre nurse, and 1 sanitary collaborator) for managing a PPH scenario. 2 different teamworks will attend a frontal lecture of 30' and afterwards they attend a scenario with actors/facilitators (enrolled within ObGyn residents) or attend a scenario with a high-fidelity mannequin after a questionnaire indicating previous experiences and skills (at the end they accept video recording of the scenario and the use of data for scientific reasons). The teamwork is recorded and an extensive debriefing is conducted using the video records and a dataset indicating positive and negative approach. After they will answer a questionnaire indicating the use of this scenario and indicating how it is compared to reality. Personal approach to teamwork job is also described.

Eligibility Criteria:
Inclusion Criteria:

* personnel working in labour ward and surgical theatre
* Volunteers

Exclusion Criteria:

* none
Protective Effects of Propranolol in Adults

This efficacy and safety trial will examine the effects and safety of propranolol administered to adult patients with severe burn injury. The investigators hypothesize that propranolol will provide significant benefit to adults following severe burn injury at doses that are safe and do not increase risk of adverse infectious and non-infectious outcomes.

A safety and efficacy trial is needed in order to determine the safety of propranolol treatment in adult burn patients, identify which subpopulations may be most likely to benefit from propranolol treatment and to identify propranolol dose levels that are not only safe but potentially effective.

Eligibility Criteria:
Inclusion Criteria:

* ≥ 20% Total Body Surface Area (TBSA) burn with anticipated operation need on admission
* Age ≥ 18 years
* Admission within 72 hours of injury

Exclusion Criteria:

* Age \<18
* Patients unlikely to survive injury or with ;age = total burn size ≥ 130
* Electrical or deep chemical burn
* Malignancy currently undergoing treatment or history of cancer treatment within 5 years
* History of HIV or AIDS
* Presence of anoxic brain injury that is not expected to result in complete recovery
* Currently treated for Chronic Obstructive Pulmonary Disease (COPD), asthma or other chronic pulmonary conditions
* History of Congestive Heart Failure (CHF) (ejection fraction \< 20%)
* Pre-injury medications including blocking agents (alpha or beta) or other anti-arrhythmic drugs
* Pregnant women
* Prisoners
* History of cardiac arrhythmia requiring medication
* Medical condition requiring glucocorticoid treatment
* Patients with concurrent conditions that in the opinion of the investigator may compromise patient safety or study objectives
Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies

For micro residual disease (MRD) positive patients who have undergone at least 2 cycles chemotherapies for their CD19+ B-cell malignancies, there would be much more risks for them to receive hematological stem cell transplantation (HSCT) than MRD- patients. In order to reduce HSCT-related adverse events for these kind of patients, investigators plan to conduct CAR-T therapies on them first to make them achieve MRD- statuses, and then transfer them to HSCT.

In order to improve prognoses for MRD+ patients who have undergone at least 2 cycles chemotherapies, patients will receive CAR-T therapy before HSCT, once they achieve MRD- remissions, they will subsequently receive HSCT if there are no contraindications.

Eligibility Criteria:
Inclusion Criteria:

1. The patient is pathologically and histologically confirmed as CD19 + B cell tumors, and has no effective treatment options currently, such as chemotherapy or autologous hematopoietic stem cell transplantation (auto-HSCT); or patients voluntarily choose CD19 CAR-T cells as a first treatment;
2. The patient is MRD+ (\<10%) after at least two cycles of chemotherapies.
3. B cell hematological malignancies include the following three categories:

   * B-cell acute lymphocytic leukemia (B-ALL);
   * Indolent B-cell lymphoma (CLL, FL, MZL, LPL);
   * Aggressive B-cell lymphoma (DLBCL, BL, MCL);
4. \< 70 years old;
5. Expected survival time \> 6 months;
6. Female patients around childbearing age, negative pregnancy test before trial, and agreed to take effective contraceptive measures during the trial until the last visit;
7. Voluntarily participate in this experiment and sign informed consent by themselves, or legally authorized representative.

Exclusion Criteria:

1. With a history of allo-HSCT;
2. With a history of epilepsy or other central nervous system diseases;
3. The presence of clinically significant cardiovascular disease, such as uncontrolled or symptomatic arrhythmias, congestive heart failure or myocardial infarction within recent six months, or heart disease with cardiac function in any grade 3 (moderate) or 4 ( severe) (according to the New York Heart Association (NYHA) Functional Classification System);
4. Pregnant or lactating women (safety of this therapy for the unborn child is unknown);
5. Not curable active infection;
6. Patients with active hepatitis B or hepatitis C virus infection;
7. Combined use of systemic steroids within two weeks (except use of inhaled steroid recently or currently);
8. Using product of gene therapy before;
9. Creatinine\> 2.5 mg / dl (221.0 umol/L); ALT / AST\> 3 X the normal amount; Bilirubin\> 2.0 mg / dl (34.2 umol/L);
10. Patients suffering from other uncontrolled diseases, and researchers believe that the patient is not suitable for trial;
11. Patients with HIV-infection;
12. Any situation that may increase the risk of patients or interfere with test results.
Famotidine in Covid-19 Intensive Care Unit

The COVID-19 disease, caused by SARS-CoV-2 virus, started in December 2019 and created a pandemic with high mortality and morbidity. Since a fully proven treatment has not been developed, the efficacy of currently available treatments is being investigated. Famotidine, an H2Receptor blocker, is one of the drug treatments being investigated. In this study, we aimed to investigate the effect of Famotidine treatment on the clinic and mortality of Covid-19 patients treated in the intensive care unit.

The computer and written records of the patients followed in the Covid-19 Intensive Care Units of a research hospital during the pandemic process will be examined. Patients over the age of 18 who have SARS-CoV-2 mRNA detected by nasopharyngeal PCR (Polymeraze Chaine Reaction) will be included in the study. Patients with immunosuppression, end-stage renal disease, liver disease, G6PD deficiency, ALT/AST \>5, long QT syndrome in ECG, diagnosed with psoriasis, porphyria, pregnant, and allergic reactions to famotidine or similar drugs were excluded from the study. Patients' age, gender, comorbidities, smoking and APACHE II score will be recorded. Patients who were administered Famotidine 160 mg/day PO or nasogastric and were not given this treatment since their admission to the intensive care unit will be compared. The primary outcome will be the need for invasive mechanical ventilation, intensive care mortality, and both. As a secondary outcome, serum markers indicating the severity of the disease (Leukocytes, lymphocytes, neutrophils/leukocytes, platelets, ferritin, CRP, D-Dimer, fibrinogen, procalcitonin, IL-6, troponin, creatinine, AST, ALT, P/F ratio and lactate) will be recorded.

Eligibility Criteria:
Inclusion Criteria:

* Patients who have SARS-CoV-2 mRNA detected by nasopharyngeal PCR

Exclusion Criteria:

* immunosuppression
* end-stage renal disease
* liver disease
* G6PD deficiency
* long QT syndrome in ECG
* psoriasis
* porphyria
* pregnant
* allergic reactions to famotidine or similar drugs
The Greek Version of the Chronic Pain Grade Questionnaire (CPGQ)

The aim of the present study is to investigate and report on the psychometric properties of a Greek version of the Chronic Pain Grade Questionnaire (CPGQ).

The Chronic Pain Grade Questionnaire (CPGQ) is designed to evaluate overall severity of chronic pain based on two dimensions, pain intensity and pain-related disability. Currently, there is no reliable, valid and sensitive to change self-report instrument as brief and easy to understand and complete as the CPGQ available in Greek. A culturally adapted version of the CPGQ would facilitate the study of chronic pain and its implications in the Greek population and allow for cross-cultural comparisons. The aim of the present study is to examine the validity, reliability and responsiveness of a Greek version of the CPGQ in chronic hip pain sufferers.

Eligibility Criteria:
Inclusion Criteria:

* chronic hip pain (persistent or recurrent hip pain for at least 12 weeks)

Exclusion Criteria:

* severe systemic disease that is a constant threat to life
* known psychiatric disorder
* impaired cognition or dementia
* mother language other than Greek
POST URS Chemotherapy Instillation

The goal of this study is to evaluate the safety and oncological outcomes of single chemotherapy bladder instillation following endoscopic treatment for UTUC in UTUC suspected patients .The main aim is to determine the efficacy of a single, post URS, chemotherapy bladder instillation to reduce IVR.

Participants will be given single chemotherapy bladder instillation within 24h following ureteroscopy and will follow routine follow-up for IVR which will include white light cystoscopy ;patients with suspected IVR (based on either imaging or cystoscopy) will undergo TURBT.

URS is routinely used for both diagnosis and treatment of UTUC - it is used either as an initial diagnostic procedure or as a curative procedure in cases amenable for endoscopic tumor ablation; either with low-risk disease or an imperative indication due to impaired renal function.

Following extirpative surgery patients are prone to IVR. Those patients undergo routine follow-up with cystoscopy and in cases of IVR require TURBT and further management based on bladder cancer protocols. In this setting, a single post-operative bladder instillation with various chemotherapeutic agents has shown a significant reduction in IVR rates following RNU.

Retrospective evidence suggests there is an increase IVR rates following URS for UTUC.

In this study the investigators seek to evaluate the efficacy of a single, post URS, bladder instillation with chemotherapy to reduce IVR.

Eligibility Criteria:
Inclusion Criteria:

* Radiographic and/or cytological suspicion for UTUC
* Planned endoscopic procedure for treatment / diagnosis of UTUC
* Patients with bladder cancer history are eligible if meeting both following criteria:

No recurrence within the last two years Are not on active bladder irrigation protocol

* Patients with history of UTUC are eligible if last endoscopic treatment or RNU was \>1 year prior to enrollment
* Age ≥ 18 years
* Performance status ECOG 0-2

Exclusion Criteria:

* Subjects who have had bladder / prostate radiotherapy
* Subjects with bladder cancer history on active bladder irrigation protocols or with active disease within two years prior to enrollment
* Subjects with previously treated UTUC within one year prior to enrollment
* Subjects with metastatic disease